Ozempic Lawsuit Update: What You Need to Know in 2026

The litigation against the manufacturers of GLP-1 receptor agonist drugs — including Ozempic, Wegovy, Rybelsus (Novo Nordisk), and Mounjaro (Eli Lilly) — has grown into one of the largest pharmaceutical mass torts in the United States. As of early 2026, more than 3,300 cases are pending in the multidistrict litigation (MDL 3094), and new cases continue to be filed each month. If you or someone you know has experienced serious side effects from these medications, here is where things stand and what you should know.

The MDL: Where Things Stand

The GLP-1 lawsuits have been consolidated in the U.S. District Court for the Eastern District of Pennsylvania under MDL No. 3094, before Judge Gene E.K. Pratter. This consolidation allows the court to manage pretrial proceedings — including discovery, expert testimony, and key legal motions — efficiently across thousands of individual cases.

The MDL has moved through its early phases and is now progressing toward bellwether trials. Bellwether cases are a small group of representative lawsuits selected from the larger pool. They are tried individually and serve as test cases that help both sides evaluate the strength of the evidence, the range of potential outcomes, and the viability of broader resolution.

The selection of bellwether cases is a significant milestone. The outcomes of these trials will heavily influence how the remaining cases are valued and whether global settlement discussions proceed.

What Injuries Qualify

The GLP-1 litigation covers a range of serious gastrointestinal and other injuries that plaintiffs allege were caused or significantly worsened by these medications. The primary qualifying injuries include:

• Gastroparesis (stomach paralysis) — a condition where the stomach cannot empty food at a normal rate, leading to severe nausea, vomiting, abdominal pain, and malnutrition
• Intestinal obstruction — blockages in the bowel that may require emergency surgery
• Severe nausea and vomiting requiring hospitalization
• Pancreatitis — inflammation of the pancreas
• Gallbladder disease — including gallstones requiring surgical removal
• Vision loss — emerging evidence linking GLP-1 drugs to non-arteritic anterior ischemic optic neuropathy (NAION)

If you experienced any of these conditions while taking or shortly after discontinuing a GLP-1 medication, you may have grounds for a claim. For more details on the full range of injuries being pursued, visit our GLP-1 litigation overview.

The Gastric Emptying Study: Why It Matters

One of the most important pieces of evidence in many GLP-1 cases is the gastric emptying study (GES), also known as gastric emptying scintigraphy. This diagnostic test measures how quickly food moves through your stomach and is the standard method for confirming a gastroparesis diagnosis.

For litigation purposes, a documented gastric emptying study is significant because it provides objective, measurable evidence of delayed gastric motility. Cases with a confirmed GES showing delayed emptying are generally considered stronger from an evidentiary standpoint. If you have been diagnosed with gastroparesis or suspect you have the condition, ask your gastroenterologist about this test.

Case Count Growth

The pace of case filings in MDL 3094 has been steady and shows no signs of slowing. The case count has grown from roughly 1,000 cases in mid-2024 to over 3,300 as of early 2026. This growth reflects several factors:

• Increasing public awareness of GLP-1 side effects
• Additional scientific research connecting these drugs to serious injuries
• The sheer volume of patients who have used these medications — tens of millions of prescriptions have been written in the United States alone
• Growing media coverage of the litigation and its progress

As more patients recognize that their symptoms may be connected to their medication, the case count is expected to continue rising.

Bellwether Timeline and What to Expect

While specific dates are subject to change as the litigation evolves, the bellwether process is expected to move forward through 2026 and into 2027. Here is the general trajectory:

1. Case selection — A pool of representative cases is identified based on injury type, drug used, and other factors
2. Intensive discovery — Selected cases undergo focused discovery, including depositions of treating physicians and company witnesses
3. Expert reports — Both sides retain medical and scientific experts who submit detailed reports on causation and damages
4. Trial — The first bellwether trials are expected to take place, providing critical data points for the entire litigation

The bellwether results will not directly determine the outcome of every case, but they will shape expectations and create strong incentives for resolution. Historically, mass tort bellwether outcomes often lead to broader settlement frameworks.

What You Should Do Now

If you took Ozempic, Wegovy, Mounjaro, Rybelsus, or another GLP-1 receptor agonist and experienced serious gastrointestinal injuries or vision problems, consider taking these steps:

1. Preserve your medical records. Obtain copies of all records related to your GLP-1 prescription history, your diagnosis, and any treatment you received. Pharmacy records, gastroenterology notes, and hospital discharge summaries are all important.

2. Ask about diagnostic testing. If you have symptoms of gastroparesis but have not undergone a gastric emptying study, discuss this with your doctor. Objective diagnostic evidence strengthens your position.

3. Do not delay. Statutes of limitations vary by state, and the sooner you engage with the legal process, the better positioned you are to preserve evidence and meet all deadlines.

Attorney Analysis

The GLP-1 litigation is at a critical juncture. With bellwether trials on the horizon, 2026 is the year where the contours of this litigation will become clearer. From our review of the cases, the strongest claims involve patients who can document both their medication history and their injury with objective medical evidence — particularly a confirmed gastric emptying study for gastroparesis claims. What we find most compelling about this litigation is the volume of internal documents that discovery has surfaced regarding what the manufacturers knew about these risks and when they knew it. The question of adequate warning is at the heart of every case. If you have been injured by a GLP-1 drug, now is the time to have your case evaluated — before bellwether outcomes begin to shape the settlement landscape.

Research Methodology

This update is based on federal court records from MDL 3094, docket reports published by the U.S. District Court for the Eastern District of Pennsylvania, and published news coverage of the GLP-1 litigation. Case count figures are drawn from publicly available MDL statistical reports.

Limitations

The GLP-1 litigation is actively ongoing, and case counts, trial schedules, and legal strategies are subject to change as the MDL progresses. Nothing in this update should be interpreted as a prediction of specific trial outcomes or settlement values, as those remain uncertain until bellwether trials conclude and any resolution framework is established.

Take the Next Step

The GLP-1 litigation is moving forward. Whether you have already been diagnosed with gastroparesis, experienced a bowel obstruction, or are dealing with other serious side effects from Ozempic, Wegovy, or Mounjaro, understanding your legal options is the first step.

If you’ve been affected, request a free case review today.